Subsequently, Moore proposed the hypothesis that intestinal secretions might have a glycemic-lowering effect in diabetics, which was the first study to suggest an effect of intestinal secretions on blood glucose ( The 21st century has seen significant progress in GLP-1R agonist research, with liraglutide (exenatide) becoming the first GLP-1R agonist to be approved by the US Food and Drug Administration (FDA) for the treatment of T2DM in 2005 ( ) and dulaglutide (Trulicity ) have been approve ( ), with 94% homology to human GLP-1, were approved in 2019 as the first GLP-1R agonists for oral administration (Table 2)
This is one of the most common effects, especially in the first week
It works particularly well for people who have tried dietary changes and exercise without achieving sustainable results, who have been curious about Ozempic or Wegovy but found the brand-name cost prohibitive, or who prefer a structured program with physician support rather than self-directed supplementation
It suppresses glucagon, a hormone prompting glucose production in the liver, thereby minimizing excess glucose levels
How are consumer needs and expectations evolving
